Family Med Medical News about Influenza A Virus, H1N1 Subtype Vaccines

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Whole-Brain Radiation Affects Learning and Memory in Brain Cancer Patients

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

One Dose of H1N1 Vaccine Immunogenic in High Percentage of Pregnant Women. No Safety Concerns Reported During Ongoing Clinical Trial
American Family Physician, 11/06/09

According to a Nov. 2 NIH news release, the H1N1 flu vaccine elicited an immune response likely to be protective in 92 percent of pregnant women who received a single 15–microgram dose. The immune response increased to 96 percent in a group of pregnant women that received a single 30–microgram dose. The immune response seen in healthy pregnant women is comparable to that seen in nonpregnant healthy adults. According to the CDC, at least 100 pregnant women have been hospitalized in U.S. intensive care units since the H1N1 outbreak started in the spring. The deaths of 28 pregnant women have been linked to the virus. Participants in the trial ranged in age from 18–39 years and began the study while in their second or third trimester. The NIAID said no safety concerns related to the vaccine – which does not include the preservative thimerosal or any adjuvant – have arisen.

<< Previous
Misclassifying nonexempt employees as exempt can cost you

Next >>
Spider bites - Assessment and management